"second-line: loading dose(s) of other non-benzodiazepine antiseizure medications (e.g. levetiracetam, sodium valproate, phenytoin, lacosamide, etc.)"
"third-line: intubation with antiseizure medication and/or anaesthetic infusion(s) (e.g. midazolam, propofol, thiopentone, ketamine, phenobarbital, etc.)"
"neurological: neuronal injury and death via NMDA-mediated excitotoxicity, hippocampal damage, and new focal neurologic deficits (9–11%) 20,21"
"epilepsy development: occurs in 20–40% of patients after status epilepticus, with seizure-induced neuronal death serving as a substrate for epileptogenesis 20"
"cognitive and functional impairment: affects 21–61% of patients, and new neurological deficits (moderate to severe) persist at discharge in ~30% 21,25"
"encephalopathy: develops in 6–15% of patients, and status epilepticus recurrence rates reach 13–37% 20,25"
"encephalopathy: develops in 6–15% of patients, and status epilepticus recurrence rates reach 13–37% 20,25"
"neurological: neuronal injury and death via NMDA-mediated excitotoxicity, hippocampal damage, and new focal neurologic deficits (9–11%) 20,21"
Expected headings
"Complications"
"metabolic derangement (e.g. hypoglycaemia)"
"toxicity (e.g. drugs)"
"pregnancy-related (e.g. eclampsia)"
"second-line: loading dose(s) of other non-benzodiazepine antiseizure medications (e.g. levetiracetam, sodium valproate, phenytoin, lacosamide, etc.)"
"third-line: intubation with antiseizure medication and/or anaesthetic infusion(s) (e.g. midazolam, propofol, thiopentone, ketamine, phenobarbital, etc.)"